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The receptor for advanced glycation end-products (RAGEs) is associated with the malignancy of cancer. A recent study has
suggested that glyceraldehyde-derived AGEs (Glycer-AGEs) enhanced the malignancy of melanoma cells, but glucose-derived
AGEsdidnot.However,theeﬀectsofGlycer-AGEsonothercancercellsremainpoorlyunderstood,andthemolecularmechanisms
behind the above-mentioned eﬀect have not been clariﬁed. The present paper aimed to examine the eﬀect of Glycer-AGEs
on cultured lung cancer A549 cells. RAGE was expressed in A549 cells. Glycer-AGEs signiﬁcantly attenuated cell proliferation.
Furthermore, Glycer-AGEs enhanced the migration capacity of the cells by activating Rac1 via ROS and also increased their
invasion capacity. We demonstrated that Glycer-AGEs enhanced the migration and invasion of A549 cells rather than their
proliferation. These results suggest that Glycer-AGEs play a critical role in the malignancy of cancer rather than its proliferation
and are potential targets for therapeutic intervention.
1.Introduction
The main cause of treatment failure and death in cancer
patients is metastasis—the formation of secondary tumors
in organs distant from the original neoplastic cell tissue.
Adjuvant therapy of proven eﬃcacy is not currently available
for cancer patients; therefore, the search for new targets of
therapeutic reagents is required to prevent both proliferation
and metastases. During metastasis, cancer cells activate
matrix digestion and migration to allow their invasion
across basement membranes [1]. It is known that the
mode of invasion is one of the markers of the malignancy
and prognosis of cancer [2]. The receptor for advanced
glycation end-products (RAGE), a multiligand member of
the immunoglobulin superfamily of cell surface molecules,
interacts with distinct molecules implicated in homeostasis,
development, and inﬂammation [3]. RAGE binding by
ligands such as advanced glycation end-products (AGEs)
triggers the activation of key cell signaling pathways, thereby
reprogramming cellular properties. In addition, several
reports have suggested that RAGE is associated with cancer
malignancy [4, 5].
The advanced stage of the glycation process (one of
the posttranslational modiﬁcations of proteins) leads to
the formation of AGEs and plays an important role in
the pathogenesis of angiopathy in diabetic patients, aging,
and neurodegenerative diseases [6–9]. A growing body of
evidence suggests that the interaction of glyceraldehyde-
derived AGEs (Glycer-AGEs), but not glucose-derived AGEs
(Glc-AGEs), with RAGE elicits oxidative stress generation
in numerous types of cells (vascular wall cells, mesangial
cells, Schwann cells, and cortical neurons), all of which
could contribute to the pathological changes seen in diabetic
vascular complications of Alzheimer’s disease [10–13]. We
have recently found that Glycer-AGEs stimulated the growth
and migration of cultured human melanoma cells and that
anti-RAGE antibodies inhibited the tumor formation and
lung metastasis of melanoma cell xenografts and subse-
quently improved survival in athymic mice [14]. However,
the eﬀects of Glycer-AGEs on other cancer cells remains2 Journal of Oncology








Figure 1: RAGE expression by Western blot analysis. Cell lysates
(30μg of proteins/lane) were loaded onto a 10% polyacrylamide
gel. Size markers (kDa) are shown on the left. Equal protein loading
wasestimated usinganti-β-actinantibody.Thearrowindicates full-
length RAGE.
poorly understood, and the molecular mechanisms behind
their eﬀects have not been clariﬁed.
In the present study, we examined the eﬀects of Glycer-
AGEs on cultured human lung adenocarcinoma A549 cells
and showed that Glycer-AGEs enhanced their malignancy
rather than their proliferation.
2.MaterialsandMethods
2.1. Chemicals. All chemicals were commercial samples of
high purity and were used as supplied. N-acetyl-L-cysteine
(NAC) was purchased from Sigma-Aldrich (St. Louis, MO,
USA).
2.2. Preparation of Glyceraldehyde-Derived AGEs (Glycer-
AGEs). Glycer-AGEs-BSA was prepared as described pre-
viously in [15]. Brieﬂy, 25mg/ml of BSA (A0281, Sigma-
Aldrich) were incubated at 37◦C for 7 days under sterile
conditions with 0.1M glyceraldehyde (GA; Nakalai Tesque,
Kyoto,Japan)and5mMdiethylenetriamine-pentaaceticacid
(Dojindo, Kumamoto, Japan) in 0.2M phosphate buﬀer (pH
7.4). The modiﬁed albumin was then puriﬁed by PD-10
column (GE Healthcare, Buckinghamshire, England) chro-
matography and dialysis against phosphate-buﬀered saline
(PBS). Control unglycated BSA was incubated under the
same conditions except for the absence of glyceraldehyde as
a negative control. Protein concentrations were determined
with the DC protein assay reagent (Bio-Rad, Richmond,
CA, USA) using BSA as a standard. The preparations were
testedforendotoxinusingthePyrotell-Ttest(SeikagakuBio-
business, Tokyo, Japan), but no endotoxin was detected.
2.3. Cell Cultures. Human lung adenocarcinoma A549 and
hepatocellular carcinoma Hep3B cells were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM; Sigma-Aldrich)
supplemented with 10% fetal bovine serum (FBS; Equitech-
Bio, Kerrville, TX, USA) under standard cell culture con-
ditions (humidiﬁed atmosphere, 5% CO2,3 7
◦C). RAGE
vector-, which were kindly provided by Dr. Yamagishi, and
its mock vector-transfected Hep3B cells were maintained in
10%FBS/DMEMinthepresenceof700μg/mLG418(Roche,
Mannheim, Germany).
2.4. Preparation of Cell Lysate and Western Blot Analysis. The
cellswerewashedwithice-coldCa2+ andMg2+ freePBS(PBS
(-)) and subjected to lysis buﬀer (1% TritonX-100/Nonidet
P-40, 10mM sodium ﬂuoride, 1mM sodium orthovanadate,
5mM sodium pyrophosphate, 2mM EGTA, 5mM EDTA,
and 1× protease inhibitor cocktail (complete, Mini; Roche)).
Subsequently, the cell lysates were incubated on ice for 5 min
and centrifuged at 10,000g for 10min at 4◦C. Their protein
concentrations were then measured using the Bradford assay
(Bio-Rad). Cell lysates (30μg of proteins/lane) dissolved in
S D Ss a m p l eb u ﬀer (62.5mM Tris-HCl (pH 6.8), 2% SDS,
10% glycerol, and 0.01% bromophenol blue) containing 5%
2-mercaptoethanol (2-ME) were boiled for 3 min at 95
◦C,
separated by SDS-PAGE, and then electrotransferred onto
PVDF membranes (Millipore, Billerica, MA, USA). Biotiny-
lated markers (Cell Signaling, Beverly, MA, USA) were used
as molecular weight markers. The membranes were blocked
for 1h using 5% skimmed milk in PBS containing 0.05%
polyoxyethylene sorbitan monolaurate (PBS-T). After being
washed twice with PBS-T, the membranes were incubated
with goat anti-RAGE antibody (N-16) or mouse anti-β-
actin antibody (Santa Cruz, Santa Cruz, CA, USA) for 1.5h.
Subsequently,themembraneswerewashedtwicewithPBS-T
and incubated with anti-goat IgG antibody (Santa Cruz) or
anti-mouse Ig’s antibody (Biosource, Camarillo, CA, USA)
and anti-biotin antibody (Cell Signaling) for 1h. After being
washed a further two times with PBS-T, the immunoreactive
proteins were detected with ECL Plus Western Blotting
Detection Reagents (GE Healthcare) using a luminescent
image analyzer (LAS-1000UVmini; Fujiﬁlm, Tokyo, Japan).
The density of the bands was analyzed using a Multi Gauge
version 3.0 (Fujiﬁlm).
2.5. Cell Viability Assay. The cells (7×103 cells/cm2)w e r e
seeded in various plates or culture dishes (BD Biosciences,
FranklinLakes,NJ,USA)andincubatedfor24h.Thecontrol
unglycated BSA and Glycer-AGEs treatments were carried
out in 0.1% FBS/DMEM for 48 and 72h, and cell viability
was determined by the WST-1 assay. After removing the
medium, 100μL/well of 10% FBS/DMEM and 10μL/well
of WST-1 solution (5mM WST-1, 0.2mM 1-methoxy-5-
methylphenazinium, and 20mM HEPES buﬀer (pH 7.4))
(Dojindo) were added, and the cells were incubated for 2h.
Absorbance was measured at 450nm and 650nm using a
microplate reader (Labsystems Multiskan Ascent, Model No.
354; Thermo Fisher Scientiﬁc, Kanagawa,Japan), and the net
diﬀerence (A450 –A 650) was used to express cell viability.
2.6. Migration and Invasion Assay. The migration and inva-
sion capacity were evaluated in 24-well transwell chambers
and BioCoat Matrigel invasion chambers (BD Biosciences),
respectively. In both assays, the upper and lower culture



















































Figure 2: Cell viability was determined using the WST-1 assay. (a) Cells were incubated with control unglycated BSA or Glycer-AGEs for
48h. The shaded, open,a n dﬁlled bars represent the results for cells treated with PBS, control unglycated BSA, and Glycer-AGEs, respectively.
(b) Cells were incubated with control unglycated BSA or Glycer-AGEs (100μg/ml) for 48 and 72h. Data are shown as the mean ± SD (n =

















































Figure 3: The migration and invasion capacities of A549 cells were evaluated in transwell chambers and Matrigel invasion chambers,
respectively. The cells were incubated with control unglycated BSA or Glycer-AGEs for 20h (a) or 48h (b). The nonmigrating or non-
invading cells remaining above the chamber membrane were removed with cotton swabs. The cells that migrated to or invaded the opposite
side of the chamber membrane were counted. (a) Migration assay. (b) Invasion assay. Data are shown as the mean ± SD (n = 3) ∗P<. 05,
∗∗P<. 01 versus control unglycated BSA.
ﬁlters with a pore size of 8μm. Ten percent FBS was used
as a chemoattractant in the lower chamber compartments.
Before starting the invasion assay, the Matrigel matrix of the
chambers was reconstituted by adding serum-free DMEM
for 2h. In the migration assay, 1×104 cells in serum-
free DMEM with control unglycated BSA or Glycer-AGEs
(100μg/ml) were added into each of the upper chambers
for 20h. In the invasion assay, 2×104 cells in serum-free
DMEM with control unglycated BSA or Glycer-AGEs were
added to each of the upper chambers for 48h. Then, the
nonmigrating or noninvading cells on the upper side of
the chamber membranes were removed using cotton swabs.
The cells that migrated to or invaded the opposite side of the
chamber were counted.
2.7. Rac1 Activity Assay. The active form of Rac1 was detect-
ed with the EZ-Detect Rac1 Activation Kit (Pierce, Rockford,
IL, USA). This assay uses the ability of a glutathione S-
transferase (GST) fusion protein corresponding to the p21-
binding domain (PBD) of human p21 activated protein
kinase 1 (Pak1) to speciﬁcally bind to the active GTP-bound
and not the inactive GDP-bound forms of Rac1 and
Cdc42. Cell lysates were incubated with GST-Pak1-PBD and




































Figure 4: Cells were pre-incubated with or without 1mM NAC
for 30min and then additionally incubated with control unglycated
BSA or Glycer-AGEs for 1 h (a) or 20 h (b). (a) The active forms of
Rac1 were precipitated with GST-Pak1-PBD and immobilized glu-
tathione discs and analyzed by Western blotting using monoclonal
anti-Rac1 antibody. At the same time, the total Rac1 in the sample
lysates was detected, and the intensity of the band was quantiﬁed.
(b) Migration assay. Data are shown as the mean ± SD (n = 3)
∗∗P<. 01 versus control unglycated BSA, ##P<. 01 versus
Glycer-AGEs.
leaving an aliquot for measuring the levels of total Rac1.
The bound proteins were eluted in 2× S D Ss a m p l eb u ﬀer
containing 5% 2-ME for 5min at 95
◦Ca n dc h a r a c t e r i z e db y
Westernblottingusingmonoclonalanti-Rac1antibody.Rac1
activity was determined by densitometric quantiﬁcation of
the pulled-down Rac1-GTP level and normalizing it to the
level of total Rac1 detected in the sample lysates.
2.8. Real-Time Reverse Transcription-PCR (Real-Time RT-
PCR) Analysis. Total RNA was isolated from the cells with
ISOGEN (Nippon Gene, Tokyo, Japan), and 50ng of RNA
were reverse transcribed into cDNA with PrimeScript RT
reagent Kit (Takara, Shiga, Japan) using a GeneAmp PCR
System 9700 (Perkin-Elmer Applied Biosystems, Foster City,
CA, USA). Real-time PCR was performed with SYBR Premix
Ex Taq using a Smart Cycler II System (Takara). The reaction
mixture (25μL) contained 1× SYBR Premix Ex Taq, 0.2μM
PCR forward primers, 0.2μM PCR reverse primers, and
10ng of cDNA as a template. The primers used were
as follows: TGF-β:5  -GCGTGCTAATGGTGGAAACC -
3  and 5 -CGGAGCTCTGATGTGTTGAAGA-3 , MMP-2:
5 -AGTCTGAAGAGCGTGAAG-3  and 5 -CCAGGTAGG-
AGTGAGAATG-3 ,a n dβ-actin: 5 -TCCACCTCCAGC-
AGATGTGG-3 and 5 -GCATTTGCGGTGGACGAT-3 .A l l
processes were performed according to the manufacturer’s
instructions. The expression levels of target genes were cal-
culated using a relative quantiﬁcation method. β-Actin was
used as an endogenous control gene in order to normalize
target gene expression values.
2.9.MatrixMetalloproteinase-2(MMP-2)ActivityAssay. The
cells were seeded and incubated for 24h. The control
unglycated BSA and Glycer-AGEs treatments were carried
out in serum-free DMEM for 48h. The conditioned medium
was collected and used with a MMP-2 Biotrak activity
assay system (GE Healthcare). All processes were performed
according to the manufacturer’s instructions. The results
have been corrected for diﬀerences in cell number.
2.10. Statistical Analysis. All experiments were performed
in duplicate and repeated at least two to three times, with
each experiment yielding essentially identical results. Data
are expressed as the mean ± standard deviation (SD).
The signiﬁcance of diﬀerences between group means was
determined by one-way analysis of variance. P values less
than .05 were considered statistically signiﬁcantly.
3. Results
3.1. RAGE Expression in A549 Cells. To investigate whether
RAGE proteins are present in human lung adenocarcinoma
A549 cells, we carried out Western blot analysis using
anti-RAGE antibody (N-16). RAGE proteins of diﬀerent
molecular weights were detected in A549 cells (Figure 1).
InfulllengthRAGEcDNA-transfectedhumanhepatocellular
carcinoma Hep3B cells, the major band (57kDa) (indicated
by an arrow in Figure 1) represents the full-length RAGE
protein. Likewise, the full-length RAGE protein was also
detected in A549 and mock transfected Hep3B cells. No
bands were detected in a neutralization experiment using
blocking peptide (data not shown) so the other bands may
represent deglycosylated RAGE proteins.
3.2. Eﬀect of Glycer-AGEs on the Cell Viability of A549
Cells. We examined the eﬀect of Glycer-AGEs on the cell
viabilityofA549cells.Cellviabilitywasdeterminedafter48h
incubation with control unglycated BSA or Glycer-AGEs.
Twenty, 50, and 100μg/mL of Glycer-AGEs signiﬁcantly
decreased cell viability to 83, 64, and 54%, respectively,
(Figure 2(a)). In contrast, control unglycated BSA had no
eﬀect. Furthermore, Glycer-AGEs signiﬁcantly attenuated
cell proliferation (Figure 2(b)); however, no cell death was
induced by Glycer-AGEs according to cell death detection
ELISA (data not shown).
3.3. Eﬀects of Glycer-AGEs on Cell Migration and Invasion.
























































































Figure 5: (a) and (b) Cells were incubated with control unglycated BSA or Glycer-AGEs for 24 h. The levels of TGF-β (a) and MMP-2 (b)
mRNA expression were analyzed using the real-time RT-PCR method, and the result was normalized to the β-actin mRNA level. (c) and
(d) Cells were incubated with control unglycated BSA or Glycer-AGEs for 48 h. The conditioned medium was collected, and the activities of
pro-MMP-2 (c) and MMP-2 (the activated form) were measured (d). Data are shown as the mean ± SD (n = 3) ∗∗P<. 01 versus control
unglycated BSA.
and invasion. In the migration assay, the Glycer-AGEs-
treated cells showed signiﬁcantly (2.7 times higher) greater
migrationthanthecontrolunglycatedBSA-treatedcells(Fig-
ure 3(a)), and in the invasion assay, the Glycer-AGEs-treated
cells showed signiﬁcantly (3.3 times higher) greater invasion
than the control unglycated BSA-treated cells (Figure 3(b)).
When Glycer-AGEs were added to the lower chamber, there
was no eﬀect on the results of the invasion assay (data
not shown). These results suggest that Glycer-AGEs-RAGE
interaction is necessary for cell migration and invasion.
3.4. Glycer-AGEs Enhanced Rac1 Activity. Cell migration is
associated with actin reorganization, which triggers changes
in cell morphology. Rho family small GTPases are widely
accepted to be key regulators of actin reorganization and
motility [16]. Interestingly, RAGE signaling has been shown
to result in the activation of Rac1 [17–20], and the activation
of RAGE by AGEs has been shown to induce the generation
of reactive oxygen species (ROS) [21]. We used the Rac1
activation kit to assess activity levels. The Glycer-AGEs-
induced Rac1 activity was about 2 times higher than that6 Journal of Oncology
of the control unglycated BSA, and it was suppressed by
pretreatment with N-acetyl-L-cysteine (NAC), an ROS scav-
enger (Figure 4(a)). Likewise, the Glycer-AGEs-enhanced
migration capacity was also signiﬁcantly suppressed by pre-
treatment with NAC (Figure 4(b)). Thus, Glycer-AGEs-
RAGE interaction enhances migration capacity by activating
Rac1 via ROS generation.
3.5. Glycer-AGEs Enhanced the MMP-2 Activity. Members
of the matrix metalloproteinase (MMP) family are widely
accepted to be key regulators of tumor invasion [22–24]. In
particular, MMP-2 and -9, which are called gelatinases, are
key enzymes for degrading type IV collagen and are thought
to play critical roles in tumor invasion and metastasis [25].
We examined the expression of transforming growth factor-
β (TGF-β) and MMP-2 mRNA and assessed MMP-2 activity
with the MMP-2 Biotrak activity assay system. Neither the
mRNA expression of TGF-β or MMP-2 was signiﬁcantly
increased by the addition of Glycer-AGEs at 24h (Figures
5(a)and5(b)).Pro-MMP-2activitywasalsonotsigniﬁcantly
altered by the addition of Glycer-AGEs at 48h (Figure 5(c)).
However, Glycer-AGEs only increased MMP-2 (the activated
form) activity to 120% (Figure 5(d)).
4. Discussion
RAGE, which is a multiligand receptor, aﬀects diseases such
as cancer and diabetes through its ligands. Several reports
have suggested that RAGE and amphoterin are closely asso-
ciated with invasion and metastasis in cancer cells [26, 27].
AGEs have been implicated in the development and progres-
sion of diabetic angiopathies, including skin dermopathy.
However, it is still unclear which AGEs subtypes play a
pathogenetic role and which AGEs receptors mediate the
eﬀects of AGEs on cells. We have provided direct immuno-
chemical evidence for the existence of six distinct AGEs
structures within the AGEs-modiﬁed proteins and peptides
that circulate in the sera of diabetic patients. Recently, we
foundthatGlycer -A GEsperformadiv erserangeofbiological
activities on vascular wall cells, mesangial cells, Schwann
cells, and cortical neurons [10–13]. We also found that
Glycer-AGEs, but not glucose-derived AGEs (Glc-AGEs),
signiﬁcantly stimulated the growth and migration of human
melanoma cells [14]. Furthermore, the tumor formation of
melanoma cells xenografts in athymic mice was prevented by
treatment with anti-RAGE antibody. In tumor bearing-mice,
survival rates were prolonged, and spontaneous pulmonary
metastases were inhibited by treatment using anti-RAGE
antibody. In addition, Glycer-AGEs were present in the beds
of human melanoma tumors, whereas they were hardly
detected in normal skin. These results suggest that Glycer-
AGEs are involved in the growth and invasion of malignant
melanoma through their interactions with RAGE. Recently,
we found that Glycer-AGEs have the strongest binding
aﬃnity for RAGE [28, 29] and subsequently elicit oxidative
stress generation and evoke vascular inﬂammation, thereby
implicating them in accelerated atherosclerosis in diabetes
[10, 11]. Taken together, Glycer-AGEs-RAGE interactions
play an important role in the progression of melanoma cells
to malignancy. However, the eﬀects of Glycer-AGEs on other
cancer cells remain poorly understood, and the molecular
mechanisms behind these eﬀects have not been clariﬁed.
In the present study, we demonstrated that RAGE was
expressed in A549 cells. RAGE includes full-length, C-
truncated, and N-truncated RAGE [29]. The RAGE antibody
(N-16) used in this study, which recognizes the N-terminus
of RAGE, detects full-length and C-truncated RAGE. Indeed,
full-length RAGE (57kDa) was detected in A549 cells. The
other bands may have represented the de-glycosylated form
or C-truncated RAGE [30]. Next, we found that Glycer-
AGEsattenuatedcellproliferationinA549cells.Glycer-AGEs
are associated with cell cytotoxicity, but Glc-AGEs are not
[21, 31, 32]. In mesangial cells, intracellular ROS produced
by Glycer-AGEs were found to induce apoptotic cell death
[21]. However, no A549 cell death induced by Glycer-AGEs
was observed in this study. It is thought that the cytotoxicity
of Glycer-AGEs depends on the sensitivity of their target cells
to ROS. Furthermore, Glycer-AGEs enhanced the migration
and invasion activity of the A549 cells, both of which are
prominent features of cancer malignancy [2].
Glycer-AGEs induced the invasion of A549 cells across
Matrigel, indicating that matrix degradation and migration
mechanismshadbeenstimulatedinthesecells.Atthemolec-
ular level, Glycer-AGEs-induced phenomena resemble the
eﬀects of long-term oxidative stress or TGF-β. Both oxidative
stress and TGF-β are key regulators of the malignancy rather
thantheproliferationofcancercells[33–35].TGF-β strongly
induces MMP-2 expression in A549 cells [36]; however,
mRNA expression of TGF-β was not induced by Glycer-
AGEs,andthemRNAlevelsofMMP-2,whichisproducedby
TGF-β, did not change. In long-term oxidative stress, Mori
et al. showed that intracellularly produced ROS activated
Rac1 [33] and enhanced the invasion capacity of tumor cells
by activating MMP [33, 37–39] .Ar e c e n tr e p o r ts h o w e d
that sustained exposure of cells to H2O2, but not one time
exposure to H2O2, increased pro-MMP-2 activation through
the induction of membrane type 1-MMP (MT1-MMP)
expression [38]. Glycer-AGEs-RAGE signaling may cause
the sustained production of ROS. Indeed, our results also
showed that Glycer-AGEs enhanced the migration capacity
of A549 cells by activating Rac1 via ROS and increased their
invasion capacity by activating MMP-2. However, Glycer-
AGEs only increased MMP-2 (the activated form) activity to
120%. It is suggested that the activation of other MMP such
as MMP-13 may also participate in the above-mentioned
changes, and future studies are necessary to clarify this
matter.
In conclusion, we demonstrated that Glycer-AGEs en-
hanced the migration and invasion of A549 cells rather than
their proliferation. These results suggest that Glycer-AGEs
play a critical role in cancer malignancy and are potential
targets for therapeutic intervention.
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